• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

NEW DELHI: Panacea Biotec has introduced Nimulid Safeinject, a nimesulide injection, 75 mg/2 ml, for rapid treatment of post-operative pain.

"Nimulid Safeinject, a novel therapy in postoperative pain, has early onset of action and provides cumulating analgesia increasing pain relief dose after dose. The technology of Nimulid Safeinject has been patented worldwide with successful clinical trials done in India," said the Panacea Biotec Joint Managing Director, Mr Rajesh Jain, in a press note.

The intramuscular injection has convenient twice-a-day dosage, good safety and tolerability profile and causes no pain at the site of injection, added the release.

More Stories on : Announcements | Health | Pharmaceuticals | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
L&T bags HSBC contract

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line